Enveda Biosciences

Enveda Biosciences is a private, pre-clinical stage biotech founded in 2019 and headquartered in Boulder, Colorado. The company has developed an integrated AI/ML and automated laboratory platform to decode the chemical complexity of the natural world, building a vast, searchable library of plant-derived molecules to identify novel drug candidates. Its platform is designed to significantly reduce the time and cost of early-stage discovery, with internal metrics suggesting a 75% reduction in required analogs and an 11x higher success rate per scaffold compared to industry averages. Enveda is advancing a pipeline of small molecule programs, though specific therapeutic areas and phases are not publicly detailed on the reviewed website content.

Integrated AI/ML and high-throughput lab platform that organizes, translates, and applies the chemical diversity of the natural world for drug discovery. It includes a mass spectrometry-based library of plant molecules, AI for chemical identification without isolation, and automated screening to determine therapeutic properties.

Enveda competes in the broad AI-driven drug discovery sector with companies like Recursion, Exscientia, and Atomwise. Its specific focus on natural products places it against other biotechs applying modern analytics to this domain, such as Hexagon Bio, Lodo Therapeutics, and partnerships between pharma and academic natural product research groups. Differentiation is claimed through the scale and integration of its platform.